Accelerating the Validation of Predictive Liquid Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification
About
Consortium
About
Consortium
Accelerating the Validation of Predictive Liquid Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification
.jpg)
Mission
To advance early and accurate FTD diagnosis through innovative biomarkers and AI-driven tools, enabling personalized care and support.
Vision
To transform FTD diagnosis and care, enabling early intervention and personalized treatments for better patient outcomes.
We are proud to create a diagnostic tool for early FTD detection, enabling tailored care and treatment.
We are proud to create a diagnostic tool for early FTD detection, enabling tailored care and treatment.
Mission
To advance early and accurate FTD diagnosis through innovative biomarkers and AI-driven tools, enabling personalized care and support.
Vision
To transform FTD diagnosis and care, enabling early intervention and personalized treatments for better patient outcomes.
Why PREDICTFTD?
Debilitating effect
on patients and their caregivers
Frontotemporal dementia (FTD) has a debilitating effect on patients and their caregivers and leads to substantial economic costs.
15-30% of patients have familial FTD caused by known pathogenetic mutations.
For the other 70-85% of patients, termed sporadic FTD, diagnosis is slow (~3.6 years) with frequent misdiagnosis due to clinical, genetic and molecular heterogeneity.
About
Why PREDICTFTD?
Debilitating effect on
patients and their caregivers
Frontotemporal dementia (FTD) has a debilitating effect on patients and their caregivers and leads to substantial economic costs.
15-30% of patients have familial FTD caused by known pathogenetic mutations.
For the other 70-85% of patients, termed sporadic FTD, diagnosis is slow (~3.6 years) with frequent misdiagnosis due to clinical, genetic and molecular heterogeneity.
Several new approaches to solve this
___________
___________
___________
Robust Two-Stage Validation Approach
We implement a novel robust two-stage strategy for biomarker and AI algorithm validation, where phase I validates biomarkers and algorithms on a cohort of genetic and autopsied cases and phase II assesses biomarker value for diagnosis of sporadic FTD and at-risk pre-symptomatic mutation carriers.
___________
___________
___________
Multimodal clinical and liquid biomarker data
We are the first to use multimodal clinical and liquid biomarker data to train an AI-algorithm as a diagnostic tool for quick and early clinical FTD diagnosis.
___________
___________
___________
11 geographically diverse cohorts
We combine 11 geographically diverse cohorts of sporadic and familial FTD with retrospective and prospective longitudinal liquid biopsy samples and extensive clinical and behavioural data.
PREDICTFTD transforms the early diagnosis of frontotemporal dementia.
Duration
54 months
Number of partners
15
Keywords
̶ Frontotemporal dementia
̶ Liquid biomarkers
̶ Early detection
̶ Predictive AI
̶ Multimodal prediction
PREDICTFTD transforms the early diagnosis of frontotemporal dementia.
Number of partners
15
Keywords
̶ Frontotemporal dementia
̶ Liquid biomarkers
̶ Early detection
̶ Predictive AI
̶ Multimodal prediction
Duration
54 months
10 April 2025
Online Meeting
Public Involvement Board discuss different aspects of a Frontotemporal dementia diagnosis
_jpg.png)
24 January 2025
Kick-off
Day 2 of the project Kick-Off Meeting
Latest updates about the
All News
project achievements
Uniting Experts for Positive Change
Uniting Experts for Positive Change
Uniting Experts for Positive Change
About Consortium
Subscribe to the newsletter
Subscribe to the newsletter
Events
4 February 2025
Event 2
23-24 January 2025
Kick-off Meeting
Events
PREDICTFTD transforms FTD diagnosis
Offering potential for early disease confirmation, guiding treatment decisions, facilitating patient recruitment for clinical trials, guidance of patients and caregivers, and enabling preventive measures.
Contact Us
There are many ways to get in touch with us: drop us a line via the form here below, or follow us on our social media.
Uniting Experts for Positive Change
Uniting Experts for Positive Change
Uniting Experts for Positive Change
About Consortium
Funded by the European Union (PREDICTFTD, 101156175). Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
© PREDICTFTD Consortium
Privacy Policy
